- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating | 5 | Benzinga.com | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 84 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 18.03. | Virax Biolabs begins UK clinical study on T cell dysfunction | 1 | Investing.com | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 13.03. | Virax Biolabs Presents Findings On T-Cell Dysfunction In Post-Acute Infection Syndromes | 1 | RTTNews | ||
| 13.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Virax Biolabs shares T-Cell dysfunction findings | 2 | Investing.com | ||
| 05.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.02. | EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency | 4 | Benzinga.com | ||
| 25.02. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.01. | Virax Biolabs Group Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 489 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health announces distribution agreement with Virax Biolabs | 3 | Seeking Alpha | ||
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 346 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 17.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.12.24 | Virax Biolabs: Interview With COO Nigel McCracken About The Diagnostics And Detection Company | 1 | pulse2.com | ||
| 20.11.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.09.24 | Cosmos Health Inc: Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits | 231 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 16.09.24 | Cosmos Health Inc.: Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar | 270 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 28.08.24 | Pre-market Movers: Bolt Projects, Acri Capital Acquisition, JBDI, Virax Biolabs, Ambarella | 979 | AFX News | SAINT PAUL (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.50 A.M. ET).In the Green Bolt Projects Holdings, Inc. (BSLK) is up over... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,80 | +0,49 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| EVOTEC | 6,976 | -1,22 % | Evotec-Aktie mit leichten Kursgewinnen (7,086 €) | Im Plus liegt derzeit das Wertpapier von Evotec . Zuletzt zahlten Investoren für das Wertpapier 7,09 Euro. Am deutschen Aktienmarkt hat sich heute die Evotec-Aktie zwischenzeitlich um 2,99 Prozent verteuert.... ► Artikel lesen | |
| BAVARIAN NORDIC | 21,890 | +0,97 % | Bavarian Nordic: Top-Zahlen - Aktie schießt zweistellig hoch | Der deutsch-dänische Impfstoff-Hersteller Bavarian Nordic kann auf einen gelungenen Jahresstart zurückblicken. Sowohl das Geschäft mit Reise-Impfstoffen als auch das Segment "öffentliche Vorsorge" verzeichnen... ► Artikel lesen | |
| ASEP MEDICAL | 0,237 | 0,00 % | ASEP Medical Holdings Inc (2): ASEP Medical suspended by CSE | ||
| EMERGENT BIOSOLUTIONS | 4,876 | -3,64 % | Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress | ||
| GINKGO BIOWORKS | 6,700 | -4,29 % | Twist Bioscience and Ginkgo Bioworks update DNA supply deal | ||
| GENPREX | 1,820 | -100,00 % | Genprex, Inc. - S-1, General form for registration of securities | ||
| PALISADE BIO | 0,690 | -0,73 % | PALISADE BIO, INC. - 10-Q, Quarterly Report | ||
| GRITSTONE BIO | 0,016 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2024ISIN NameUS23636BAV18 DANSKE... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 5,920 | -0,34 % | Dividendenbekanntmachungen (15.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 1&1 AG DE0005545503 - 0,05 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0536 EUR ADMIRAL GROUP PLC GB00B02J6398 0,914 GBP 1,0846... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| ANNOVIS BIO | 1,468 | -3,93 % | Annovis Bio Inc.: Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results | Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| HUMACYTE | 1,875 | +0,81 % | Humacyte, Inc: Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update | - Commenced market launch and first commercial sales of Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 2,780 | 0,00 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates | SAN MATEO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.